We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.00 | 1.13% | 267.50 | 265.00 | 267.00 | 273.00 | 265.50 | 266.50 | 18,840 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
07/9/2018 00:53 | Great news from HCM this week although the positive reaction was very short-lived! Judging from the close in the US at the end of the last session we are in for a rough day when the UK opens. If we drop down to the 4000-4100p area I may well have to average down. In the long term that should be a wise move, I hope! | lauders | |
07/9/2018 00:00 | An interesting article just published by Evaluate hxxp://www.evaluate. Interesting, although I do not agree with this point:- "Presumably if fruquintinib is left on its own outside China Chi-Med will have to seek a new partner." It seems the author isn't aware that Ci-Med is setting up the required infrastructure and regulatory Teams to avoid the need to partner if Lilly does not take up ex-China rights. | nerdofsteel | |
06/9/2018 22:13 | The US close at $26.55 is equivalent to £41.I keep an eye on charts but I’m no devotee.However,that chart suggests that the price would like to revisit £41.I hope I’m wrong and if it does I hope the visitation is a short one. All things Chinese have been under pressure of late.Alibaba is down near a quarter in just a few months but this is in large part due to a falling renminbi.Quite why HCM has come in for a beating is not immediately obvious.Better to travel than arrive ahead of drug approval?Well,we hardly had a spate of outperformance ahead of yesterday’s RNS did we?I guess stocks like HCM can be vulnerable in tired markets but I’m searching for explanations. | steeplejack | |
06/9/2018 20:37 | Head and shoulders.... probably complete now. I'm no expert on chart patterns at all, but isn't tjat a H&S formed, which would signal a further fall? | kazoom | |
06/9/2018 20:02 | Head and shoulders.... probably complete now. | reptile3 | |
06/9/2018 18:56 | Makes no sense to me at all. Annoying though | mad foetus | |
06/9/2018 17:59 | Everything else, other than the share price, appears positive. Big drop in share price on the other side of the pond, today. Is yesterdsy’s approval news not good enough for the big buyers? Disheartened sellers, perhaps. | sportii | |
06/9/2018 07:10 | Daily Telegraph article in today's business section discussing things."We are going to see the Chinese pharmaceutical industry really develop from an emerging market to being the most important market globally," said Mr Hogg. "It is inevitable."So when will China become home to the new Boston or London? "Give it five, 10 years and Shanghai will be up there," said Mr Hogg. "It's been a long journey for us to get where we are, but we are also excited about the things to come. This is just the start." | steeplejack | |
06/9/2018 03:31 | I agree that anything with "China" in it is being avoided, there is a selloff at the moment in Asian markets and we have suffered but the Company's pipeline and growth path will mean its growth is assured. We had a lull like this 10 years ago when there was 4 years of stagnation, only to then quadruple in the space of 4 years. The same will probably happen again as we get more approvals. Savolitinib is the big one of course, especially if we get BT designation in the U.S. That will be huge. | nerdofsteel | |
06/9/2018 02:15 | are you suggesting that fruq, although trialled on 3rd line and approved for that, may also be used (trialled) for 1st or 2nd line patients instead of, or alongside, chemo?? if appropriate, that would reach far more patients but surely new lengthy trials and approvals would be necessary? | shaker44 | |
05/9/2018 23:56 | Median os and pfs in 3rd line treatment results can be confusing. Patients in 3rd line trials are very sick people most with a few months prognosis. This result for fruquintib is comparable to an early trial result for tagrisso (aura3 I think) in lung cancer, 2nd line. Look at tagrisso now being given to treatment-naive (1st line) patients. The os and pfs is so much better for these patients because the drug has relatively little disease to deal with instead of losing half your patients before you really got started - a few months pfs means so much in 3rd line. Tagrisso looks like producing $6billion a year at its peak in all the different indications it will be used in. Fruquintinib is an important drug but its true potential is not yet understood, hense the tepid response to its approval. Having invested back in 2016 simply because of my own research into my own lymphoma led me to hcm, I realise now that this is when it all kicks off and the fun starts! This approval is pivotal. In for the long term (I hope). | petersplants | |
05/9/2018 18:22 | NoS, I agree, surprised (but not!) that we ended down today. Having been with HCM since the one pound days I think the future looks rosier than ever. Out of interest, do you live in HK or visiting? Had the pleasure of visiting there last December. | cisk | |
05/9/2018 16:24 | Anything with the word "China" in it is being avoided... | dbadvn | |
05/9/2018 15:32 | it seems to be that the market is turning Good news mostly ignored, bad news punished severely | malcontent | |
05/9/2018 15:26 | Perhaps, there are no buyers left! | sportii | |
05/9/2018 13:44 | Well, wasn't expecting a down day! | mad foetus | |
05/9/2018 12:16 | thanks. I get all that but the real benefit of any cancer drug is the odds of it significantly extending life. despite all the news we see almost daily, of new wonder drugs for cancer,the gold standard colorectal chemo,oxaplatin, in use globally today, was first developed in 1976!! then 20 years to get it to market!!. | shaker44 | |
05/9/2018 11:57 | S44, I find it practically impenetrable to understand the technicalities of a pharmaceutical drug. It's so highly technical and largely beyond my comprehension that I have to rely largely on analysts and company announcements. I believe fruquintinib is the latest in a class of cancer drugs called VEGFR inhibitors, The drug works by blocking certain kinases, a type of enzyme, that send growth signals to form blood vessels. Most similar drugs target not just VEGFR but also other pathways to inhibit several other kinases. That can be a bad thing, because these kinases play a role in healthy cell function, and so inhibiting them can result in side effects that make the drugs difficult for patients to tolerate. Chi-Med developed fruquintinib to try to get around this problem. It only targets VEGFR, with the goal of fewer side effects. It was a feature meant to make fruquintinib competitive on the global stage. It is therefore regarded as a very safe, clean drug. So I believe this drug is somewhat of a technical break through and is best-in-class. But a much greater opportunity lies with combining this drug with other drugs which is under evaluation in the US (I think!) There is a wealth of technical data available from the company's website. | carcosa | |
05/9/2018 11:47 | But I imagine better tolerability/less side effects would be a more meaningful benefit | mad foetus | |
05/9/2018 11:33 | thanks. I didnt spot the still alive after 15 months data. clearly more interesting but also makes the median seem very low. personally If I had been through 2-rounds of very debilitating chemo and my oncologist said I would probably survive 5 months or 7 if I took this new drug, it wouldnt excite me. so surely there must be more to it. there must have been many very early deaths in the trial for the median to be so low, in which case, in the real world patients would be better targetted to those with a better risk profile. | shaker44 | |
05/9/2018 11:21 | Am willing to be corrected but my understanding is that the numbers you refer to are the median overall survival rate i.e 50% of patients are alive after 7 months as opposed to 5 months. The Median progression-free survival (The length of time during and after the treatment, that a patient lives with the disease but it does not get worse)was also significantly increased to 3.7 months from 1.8 months The study showed nearly 30% of patients were still alive after 15 months as opposed to about 18% on placebo. At times like this it's perhaps better to consult a statistician than an investor lol! | carcosa | |
05/9/2018 11:02 | I think the other aspects are its improved tolerability and also multiple uses. On tolerability alone it should become the first port of call for those needing this treatment (though obvs it is for those for whom first line treatment has failed). But once launched for one indication the approvals for others should follow quickly as safety has been proven. | mad foetus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions